Reply to Pandita et al

Susan A Olender¹, Katherine K Perez^{2

3}, Anand P Chokkalingam^{4

5}, Richard H Haubrich⁶

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York, USA.
² Department of Pharmacy, Houston Methodist, Houston, Texas, USA.
³ Department of Pathology and Genomic Medicine, Houston Methodist, Houston, Texas, USA.
⁴ Department of Clinical Research, Foster City, California, USA.
⁵ Department of Gilead Sciences, Foster City, California, USA.
⁶ Medical Affairs Research, Gilead Sciences, Foster City, California, USA.

Comment

Susan A Olender et al. Clin Infect Dis. 2021.

. 2021 Jul 15;73(2):357.

doi: 10.1093/cid/ciaa1350.

Susan A Olender¹, Katherine K Perez^{2

3}, Anand P Chokkalingam^{4

5}, Richard H Haubrich⁶

¹ Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York, USA.
² Department of Pharmacy, Houston Methodist, Houston, Texas, USA.
³ Department of Pathology and Genomic Medicine, Houston Methodist, Houston, Texas, USA.
⁴ Department of Clinical Research, Foster City, California, USA.
⁵ Department of Gilead Sciences, Foster City, California, USA.
⁶ Medical Affairs Research, Gilead Sciences, Foster City, California, USA.

No abstract available

Comment on

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Hu H, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Diaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, Bernardino JI; GS-US-540–5773 and GS-US-540–5807 Investigators. Olender SA, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4166-e4174. doi: 10.1093/cid/ciaa1041. Clin Infect Dis. 2021. PMID: 32706859 Free PMC article. Clinical Trial.
Call for Action: Racial Disparities in Clinical Research.
Pandita A, Gil RM, Farmakiotis D. Pandita A, et al. Clin Infect Dis. 2021 Jul 15;73(2):356-357. doi: 10.1093/cid/ciaa1349. Clin Infect Dis. 2021. PMID: 32894751 No abstract available.

1. Pandita A, Macias Gil R, Farmakiotis D. Call for action: racial disparities in clinical research. Clin Infect Dis 2020; doi:10.1093/cid/ciaa1349. - DOI - PubMed
1. Olender SA, Perez KK, Go AS, et al. . Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis 2020; doi:10.1093/cid/ciaa1041. - DOI - PMC - PubMed
1. Lee SJ, Grobe JE, Tiro JA. Assessing race and ethnicity data quality across cancer registries and EMRs in two hospitals. J Am Med Inform Assoc 2016; 23:627–34. - PMC - PubMed
1. George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health 2014; 104:e16–31. - PMC - PubMed
1. Mullane K, Criner GJ, Richterman AG, et al. . Racial/ethnic disparities not observed in clinical outcomes with remdesivir treatment. Abstract OA24990 presented at Virtual COVID-19 Conference, Virtual Meeting, 10–11 July 2020.